The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Non-Small Cell Lung Cancer (NSCLC) Global Market ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

Immutep's ASX-listed stock fell more than 88% on the news that its phase 3 trial TACTI-004 of LAG-3 inhibitor eftilagimod alfa (efti) as a first-line treatment for non-small cell lung cancer (NSCLC) ...